As our nation deals with the unprecedented effects of coronavirus, impacts to public events, work routines, commerce, and general human interaction are occurring in ways we may never have imagined. Many of the events listed here have altered plans and we encourage you to visit their websites for the latest information. From our team at CSI to you, your families, friends, and coworkers, please accept our sincere wishes for good health, safety, and a resumption of activities as soon as possible. We will get through this together but in the meantime please know that we are still available to you, so please do not hesitate to reach out.
340b Coalition Winter Conference
January 30, 2019 - February 1, 2019
For those of us dedicated to helping patients in need through 340B, 2019 promises to be a time of change and challenge. With help from our allies on Capitol Hill and across the country we will continue to ensure 340B remains an integral part of our national health care safety net.
In the past 12 months there have been multiple congressional hearings – where our leaders were able to talk about the critical role 340B plays in caring for patients and communities – and a dozen legislative proposals were rolled out. Regulatory challenges have led 340B providers to ask the courts to ensure a level playing field. And, in October, the CEOs of more than 700 340B hospitals from every state in the country called on the bipartisan leaders of Congress to #Protect340B.
Our collective efforts to strengthen 340B will be front and center in San Diego January 30-February 1 for the 2019 340B Coalition Winter Conference.
Some of the areas we will be focusing on include an update on what’s new in HRSA’s 340B audits; trends in state Medicaid policies around 340B; and new developments in contract pharmacy, inventory management, and specialty pharmacy. We will hear from national experts on the response to the national epidemic of opioid abuse and the pursuit of health equity. And there will be timely updates on the ever-changing environment in Washington D.C. including:
The legislative front – A brand new Congress will take its seats in January with dozens of newly elected Senators and Representatives. The need to educate our policymakers on the importance of 340B will be greater than ever.
The regulatory front – President Trump’s efforts to rein in drug costs will continue with a series of regulatory initiatives. The push for greater transparency and accountability on the part of manufacturers will also move forward.